Tin tức & Cập nhật

Treatment with tofacitinib demonstrates effectiveness in patients with Blau syndrome (BS) who are resistant to tumor necrosis factor inhibitors (TNFi) or corticosteroids, reports a recent study.

Bimagrumab, when combined with semaglutide, enhances weight loss while preserving lean mass better than either treatment alone in the phase IIb BELIEVE study presented at ADA 2025.

New drug applications approved by US FDA as of 16-31 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New drug applications approved by US FDA as of 1-15 July 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New research suggests that in older adults with type 2 diabetes (T2D) who are taking metformin, using dipeptidyl peptidase-4 inhibitors (DPP4is) and glucagon-like peptide-1 receptor agonists (GLP1RAs) has a null effect on the risk of COVID-19 infection. However, among those who do contract the virus, the use of these drugs appears to lower the risk of hospitalization.

A recent study in the Philippines has identified key demographic and behavioural patterns among Filipino men who have sex with men (MSM) and transgender individuals (TGIs) regarding their awareness of pre-exposure prophylaxis (PrEP) and modality preferences.

A recent study suggests that the use of hormone therapy does not contribute to increased women with severe symptoms of COVID-19.

Combined treatment with dapagliflozin and spironolactone results in greater reductions in N-terminal pro–B-type natriuretic peptide (NT-proBNP) than dapagliflozine alone in patients with heart failure with preserved ejection fraction (HFpEF), a recent study has shown.